Mounjaro®
Starting from £179.99/mo
Start journey Learn moreGetting the most weight loss from Wegovy means pairing the medicine with the right habits from day one. Semaglutide reduces appetite and slows digestion, but clinical trial participants who combined it with consistent dietary changes and regular activity lost significantly more than those who relied on the injection alone. Wegovy is a prescription-only medicine; a clinician will assess whether it is appropriate for you before any treatment begins.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
Picture this: you're two weeks in, the nausea has mostly settled, and you notice you're simply not hungry at lunchtime. That reduced appetite is the medicine doing its job. The question is what you do with that window.
Semaglutide works by activating GLP-1 receptors, slowing gastric emptying and signalling fullness to the brain. The appetite suppression is real, but it does not make food choices for you. Clinical trial participants who achieved the strongest outcomes tended to use the reduced hunger as an opportunity to shift the composition of what they ate, not just the quantity. Prioritising protein at each meal (roughly 25–30g per sitting) helps preserve muscle while fat mass falls. Muscle tissue burns more calories at rest, so protecting it pays dividends well beyond the treatment period.
Hydration matters more than most people expect. Nausea, one of the most common early side effects described on the NHS semaglutide medicines page, is often worse when people are underdrinking. Aim for water steadily through the day rather than in large gulps. A quick check: if your urine is pale straw-coloured, you're on track, if it's dark, drink more before your next meal. That one visual check takes under a minute and is a reliable daily feedback loop.
The broader picture of getting the most from a Wegovy course comes down to treating the medicine as the tool it is, not the whole plan.
Wegovy follows a titration schedule, 0.25mg, then 0.5mg, 1.0mg, 1.7mg and 2.4mg, stepped roughly every four weeks by your prescriber. Some patients want to move faster; the titration exists partly to reduce gastrointestinal side effects, but also because the body adapts more efficiently at each level before the next increase.
Most of the weight loss data, including the STEP 1 results published in the New England Journal of Medicine, comes from participants who completed the full schedule. Rushing a dose increase or skipping steps because results feel slow at 0.5mg is likely to increase side effects and could reduce overall outcomes. If you are on a higher dose and losing more slowly than expected, the answer is rarely the dose, it is more often sleep, stress, alcohol, or the gradual creep back into old eating patterns as the novelty wears off.
The pattern of when weight loss peaks on Wegovy is worth understanding before you start, so that a slower week at month four does not feel like failure. Weight loss on this medicine tends to be fastest in the first 20 weeks or so, then continues at a more moderate rate. Plateaus are normal and do not mean the treatment has stopped working.
What does your prescriber need from you? Honest reporting. If side effects are significant, there is clinical flexibility in how quickly you move through the schedule. A prescriber who knows the full picture can make better decisions than one who hears only what you think they want to hear.
No clinical trial for Wegovy ran without a lifestyle component. Every participant received dietary counselling and activity support alongside the injection. That is not a coincidence; the licence itself specifies use alongside a reduced-calorie diet and increased physical activity.
In practice, most people find appetite suppression makes the dietary piece easier than they expected. The harder part is the activity. Strength training two or three times a week does not need to be a gym programme, resistance bands, bodyweight exercises, or weighted walks all count. The goal is to give your muscles a reason to stay while the calorie deficit does its work.
Sleep is under-discussed in this context. Poor sleep raises ghrelin, a hunger hormone, which partially counteracts the appetite suppression semaglutide provides. Seven to nine hours is the standard clinical recommendation; if that feels out of reach, it is worth raising with your prescriber rather than assuming it does not matter.
People who get the most out of Wegovy tend to treat it as the start of a different relationship with food and movement, not a temporary fix. That framing is not motivational fluff, it is what the evidence suggests. Many people also find that using the Wegovy weight loss app helps them stay consistent between appointments by tracking progress and nudging healthier habits. For a broader look at the maximum weight loss people achieve, the outcomes data from clinical trials gives a realistic reference point. The practical toolkit for maximising your Wegovy results covers this in more detail, including what to do when progress stalls.
If you are considering Wegovy and want to understand what private treatment involves, you can see how Wegovy costs are structured and what is included in a properly supervised course. When you are ready, start your free consultation and our prescribers will assess whether Wegovy is the right fit for you.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.